CLINICAL EFFICACY OF RECOMBINANT FACTOR VIII FC FUSION PROTEIN IN HAEMOPHILIA A PATIENT RECEIVING ON DEMAND TREATMENT ONLY

Saima Zahir, Tahira Zafar, Altaf Hussain, Hamid Saeed Malik, Pervez Ahmed, Saleem Ahmed Khan
Armed Forces Institute of Pathology/National University of Medical Sciences (NUMS) Rawalpindi Pakistan

ABSTRACT

Objective: To evaluate the efficacy of recombinant factor VIII FC fusion protein in haemophilia A patient receiving on demand treatment only.

Study Design: Comparative cross sectional study.

Place and Duration of Study: Department of Hematology, Armed Forces Institute of Pathology and Pakistan Hemophilia Welfare Society, Rawalpindi, from Jun to Dec 2017.

Methodology: Eighty-nine male patients of Hemophilia A already receiving recombinant factor VIII (20-30 Units/kg) on demand, with no history of inhibitors were included in study. Patients were divided as per age into paediatric and adult group and also on the basis of their basal factor VIII levels into severe, moderate and mild groups. Same patients were switched to recombinant factor VIII FC fusion protein (20-30 Units/kg) and its efficacy was measured and compared with recombinant Factor VIII in terms of dose requirement, injections, bleeds in six month period, presence of inhibitors and side effects.

Results: Eighty nine male patients were studied. There was significant reduction in dose from median value of 5750 units for group I to 4000 units for group II. Number of bleed in six month period were reduced from 5.3 in group I to 4.5 in group II. Number of injections were reduced on average to 1-2 injection per bleed in group II. No inhibitors were detected in group II.

Conclusion: rFVIII Fc fusion protein has prolong activity and results in reduction of total dose, number of bleed, dose per bleed and has reduced antigenecity.

Keywords: Hemophilia A, Recombinant factor VIII, Recombinant factor VIII Fc fusion protein.

INTRODUCTION

Hemophilia A is X linked recessive inherited disease cause by deficiency of coagulation factor VIII (FVIII)1. It is characterized by bleeding into joints, muscles and body cavities such as CNS2. When inadequately treated, this leads to chronic arthropathy, disability and increased risk of death3. Bleeding may be spontaneous or traumatic. Patients with severe hemophilia A (factor level <1%) typically present with spontaneous bleeding typically into joints and muscles, whereas patients with moderate disease (factor level 1-5%) or mild disease (factor level 5-50%) only be diagnosed later in life following a haemostatic challenge4,5.

The mainstay of treatment for individuals with severe hemophilia A is replacement therapy with coagulation factor VIII6. According to world hemophilia federation different treatment protocols are available which include prophylactic treatment (given twice or thrice weekly) and on demand therapy which is given when patient present with a bleeding episode7. Recombinant factor VIII (rFVIII) products have been available as replacement therapy in hemophilia A since 1990s8. However conventional FVIII products which have half life of 12 hours, require frequent intravenous infusion of replacement factor to maintain protective FVIII levels above 1%.9,10.

Recombinant factor VIII Fc Fusion molecule is composed of a single molecule of B-domain deleted recombinant factor VIII (rFVIII) covalently fused to the dimeric Fc domain of IgG1 which binds the neonatal Fc receptor, and utilizes the IgG recycling pathway to extend plasma half life3,10. Recombinant FVIII Fc fusion protein has approximately 1.5 fold longer half life than rFVIII.
and overall improve management and quality of life of Hemophilia A patients\textsuperscript{10}.

In this study we compare clinical efficacy of recombinant factor VIII to recombinant factor VIII Fc fusion protein which has extended half life of 19 hours and less antigenic.

**METHODOLOGY**

This was comparative cross sectional study conducted at Armed forces institute of Pathology and Pakistan society of Hemophilia Islamabad/ Rawalpindi from June 2017 to December 2017 using nonprobability Consecutive sampling technique. The protocol was approved by the local institutional review boards (FC.HEM 16,-12/ READ-IRB/1 7 1286). Written informed consent was obtained from the patients.

Sample size was calculated using WHO calculator for sample size. Eighty nine patients who were diagnosed cases of hemophilia A, aged above 3 years with no history of co-morbid and inhibitors to factor VIII were receiving rFVIII for at least last six months, were included in study. Exclusion criteria include patients below 3 years of age, presence of inhibitors to factor VIII, any co-morbid, and known hemophiliacs undergoing surgical treatment. To avoid any change in genetic makeup same patients who were receiving recombinant factor VIII for at least 06 six month were switched to recombinant factor VIII Fc fusion protein.

Patients were divided into different groups according to age and severity of disease. As per age patients were divided into 2 groups. Group A below and equal to 12 years (n=44\%) and Group B included patients above 12 years (n=56\%). According to severity as per WHO classification patients were further divided into mild (n=09), moderate (n=40) and severe group (n=40). All groups were compared in terms of number of bleeds, number of injections required per bleed, dose per bleed, total dose and side effects in six month period.

Patients’ previous data with recombinant factor VIII at dose of 20-30 IU/kg had been analyzed for number of bleeds, number of injections, dose required /bleed and total dose in 6 months. Same patients had been switched to rFVIII Fc fusion protein at dose of 20-30 IU/kg and followed for six months for number of bleeds, injections per bleed, dose required per bleed and any adverse events. At the end of study individuals were screened for the presence of inhibitors. About 1.8 ml of blood in 0.2ml of tri-sodium citrate was collected in laboratory. Screening was done for both immediate and delayed inhibitors by mixing studies by aPTT method. Data was analyzed using SPSS version 24. Frequency and percentages were calculated for qualitative data, mean ± SD was calculated for quantitative data. Paired sample t test was for comparison of mean difference. A p-value ≤0.05 was considered as significant.

**RESULTS**

A total of 89 male patients were included in this study, mean age of the patients was 16.07 ± (SD=2.2) years, mean age of group A was 8 ± (SD=3) years and group B was 22 ± (SD=3) years. Mean dose of RF VIII in pediatric groups was

| Table-I: Comparison of mean difference of both age groups in Recombinant factor VIII and Recombinant factor VIII Fc fusion protein. |
|-----------------|-----------------|-----------------|------------------|
| Age Group       | RF VIII         | RF VIII FC      | p-value          |
|                 | Mean ± SD (n=39)| Mean ± SD (n=50)|                  |
| Dose            |                 |                 |                  |
| ≤12 Years       | 4207.69 ± 388.720 | 3192.31 ± 276.51 | 0.014            |
| >12 Years       | 7333.0 ± 417.72 | 5889.80 ± 338.68 | 0.023            |
| Injection       |                 |                 |                  |
| ≤12 Years       | 6.82 ± 0.78     | 5.23 ± 2.69     | 0.025            |
| >12 Years       | 8.60 ± 2.83     | 6.10 ± 3.43     | 0.001            |
| Bleeding        |                 |                 |                  |
| ≤12 Years       | 4.44 ± 2.45     | 4.13 ± 2.43     | 0.02             |
| >12 Years       | 5.29 ± 2.98     | 4.76 ± 3.54     | 0.001            |

4207.69 ± (SD=388.720) IU and in adult group was 7333.0 ± (SD=417.72) IU (p=0.014), mean dose of RF VIII FC in pediatric groups was 3192.31 ± (SD=276) IU (p=0.014), and in adult group was 5889.80 ± (SD=338.68IU) (p=0.023). A significant
reduction in number of injections, bleeding, traumatic and Spontaneous was seen in both age groups, shown in table.

Table-II shows the comparison of RF VIII and RF VIII FC according severity of disease, significant statistical difference in total dose, number of bleeds and injections required in all three groups.

| Table-II: Comparison of RF VIII and RF VIII FC fusion protein according severity of disease. |
|---------------------------------------------------------------|
|                | RF VIII Mean ± SD (n=39) | RF VIII FC Mean ± SD (n=50) | p-value |
|----------------|--------------------------|----------------------------|---------|
| **Total Dose in Six Month Period** |                      |                             |         |
| Mild           | 6083.33 ± 5452.92 IU     | 4888.89 ± 3196.95 IU       | 0.122   |
| Moderate       | 5037.50 ± 3376.74 IU     | 4418.50 ± 3603.71 IU       | 0.001   |
| Severe         | 6858.75 ± 4626.35 IU     | 4956.25 ± 3290.37 IU       | 0.002   |
| **Number of Injections in Six Month Period** |                      |                             |         |
| Mild           | 7.56 ± 5.19              | 6.56 ± 5.19                | 0.585   |
| Moderate       | 6.68 ± 4.053             | 5.40 ± 3.82                | 0.014   |
| Severe         | 9.03 ± 5.42              | 5.85 ± 2.82                | 0.001   |
| **Bleeding Rate** |                      |                             |         |
| Mild           | 5.67 ± 4.03              | 5.22 ± 4.02                | 0.702   |
| Moderate       | 4.70 ± 2.59              | 4.28 ± 2.49                | 0.091   |
| Severe         | 5.75 ± 2.77              | 4.53 ± 2.1                 | 0.001   |

**DISCUSSION**

Extended half life of recombinant FVIII Fc fusion protein has overall improve management and quality of life of Hemophilia A patients\(^{11}\). Various studies have shown the rFVIII fc was well tolerated without serious adverse events related to the drug\(^{12}\).

Development of alloantibody to the replacement therapy is the most challenging complication\(^{13}\). These alloantibody neutralizes the coagulant activity of infused factor FVIII in up to 30% of previously untreated patients with severe hemophilia A, typically during first 50 exposure days to therapeutic products containing the deficient factor VIII\(^{14}\). Inhibitor formation is a T-cell response to foreign infused FVIII that renders life saving factor treatment ineffective and results in poorly controlled bleeding with twice the hospitalization and 10 times the cost of non inhibitor patients\(^{15}\).

In developed countries usually prophylactic treatment is given with regular follow up\(^{16}\). But in developing world, where there is lack of health facilities and limited resources on demand treatment is treatment of choice. In this scenario factor products with extended life can lead to not only reduction in number of injection and dosage but also establishment of arthropathy can be reduced.

This study has confirmed the findings of previous studies in Hemophilia A patients in which recombinant FVIII Fc fusion protein has resulted in decrease number of bleeds, injections and total dose. Patients had experienced minimal side effects and no development of inhibitors\(^{8,9}\).

Development of rFVIII with extended half life improves the management of hemophilia and improves quality of life of patients by reducing the burden of frequent intravenous injections\(^{17}\). Moreover, possibility of maintaining high trough levels effectively cover major surgical procedures with few injections and low factor consumption\(^{18}\). Although prophylaxis with regular administration of FVIII in order to prevent joint and severe life and limb threatening bleeds is the recommended treatment for patients with severe hemophilia A\(^{16}\). But in resource constraint countries like Pakistan only limited data is available about hemophilia A patients. Availability and accessibility to factor VIII, lack of knowledge of disease and scarce resources for diagnosis are main reasons which results in poor patient care and treatment. Prophylaxis is still not possible due to above mentioned reasons. Here on demand treatment is main choice of treatment. Most patients already develop arthropathy before diagnosis and initiation of treatment.

Data regarding recombinant FVIII Fc fusion protein is very scarce for patients receiving on demand treatment only. However results of our study are comparable with other results of episodic arms of treatment with rFVIII Fc fusion protein in multiple studies\(^3\). The phase I/II trial (NCT 01027377) shows that rFVIII was well tole-
rated without serious adverse events related to the drug. None of the subjects develop inhibitors to the rFVIII Fc fusion protein. Patients in arm 3 receiving rFVIII Fc fusion protein at dose of 10-50IU/kg showed significant reduction in annual bleeding rate\(^3\). Similar results were obtained by Shapiro et al, which also showed reduction in annual bleeding rate of zero percent in patient receiving prophylaxis and on demand treatment\(^5\).

This results are comparable with study conducted by Young et al\(^9\). In our study 85% patients require single dose for each bleeding episode which are compare able with 81.0% of subjects receiving single dose per bleed in study conducted by young et al\(^9\). Bleeding episodes of 75% patients were controlled with single injection which are comparable with our results\(^3\). Similar results were obtained in A-LONG study by Shapiro et al, in his study 98% patients required single dose for treatment of bleeding episode\(^5\).

Annual bleeding rate is reduced in patients receiving rFVIII Fc fusion protein in all groups and these results are comparable with studies conducted by Young at al where while receiving prophylaxis with rFVIII Fc fusion protein ABR were reduced to zero, and Shapiro et al and Berntorp\(^5,8,10\).

The most challenging complication of replacement therapy is the occurrence of alloantibodies that neutralizes factor VIII in upto 30% patients receiving rFVIII\(^4,7,9,11\). Inhibitors compromise the ability to manage hemorrhage, which results in increased morbidity and disability for patients and cost\(^9\). Risk factors for development of inhibitors can be related to patient (i.e; age of patient, race, positive family history, and factor VIII genotype) or can be related to treatment (i.e; high intensity treatment at young age)\(^7\). In our study 40 patients had been evaluated for presence of inhibitors at the end of study, none of them had developed inhibitors which confirms the low immunogenicity of rFVIII Fc fusion protein as shown in other studies. No inhibitors were detected in study conducted by Young’s et al in Children’s Hospital Los Angeles, University of Southern California and Berntorp et al\(^9,10\).

**CONCLUSION**

rFVIII Fc Fusion Protein has prolonged half life which results in significant dose reduction and number of injections. It is a better option for patients receiving on demand treatment from far flung and resource constrained areas. However on demand treatment has no effect on arthropathy once it is established. Low dose prophylaxis with long acting Fc Fusion protein can be a choice to reduce hemophilia induced arthropathy.

**CONFLICT OF INTEREST**

The study has no conflict of interest to declare by any author.

**REFERENCES**

1. Lambert T, Benson G, Dolan G, Hermans C. Practical aspects of extended half-life products for the treatment of haemophilia. Ther Adv Hematol 2018; 9(9): 295-308.
2. Kim SK, Yoo KY, Lee KS, Hwang T, Choi YM, Choi EJ, et al. Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (Green Gene F™) in Korean Patients with Hemophilia A: Data from a Post marketing Surveillance Study. J Korean Med Sci 2018; 33(1): 1-5.
3. Mahlangu J, Powell JS, Ragni MV, Chowdary P, Josephson NC, Pabinger I, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014; 123(3): 317-25.
4. Hartmann J, Croteau SE. Clinical trials update: Innovations in hemophilia therapy. Am J Hematol 2016; 91(12): 1252-60.
5. Shiparo DA et al. Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A- LONg study subjects with hemophilia A. Haemophilia 2017; 23(3): 392-99.
6. Miners AH, Krishnan S, Pasi KJ. Predicting the outcomes of using longer-acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis. J Thromb Haemost 2016; 14(11): 2141-47.
7. Powell JS, Josephson NC, Quon D, Ragni MV, Cheng G, Li E, et al. Safety and prolonged activity of recombinant factor VIII fc fusion protein in haemophilia A patient. Blood 2012; 119(13): 3051-57.
8. Mancuso ME, Santagostino E. Outcome of clinical trials with new extended Half-Life FVIII/IX concentrates. J Clin Med 2017; 6(4): 39-41.
9. Young G, Mahlangu J, Kulkarni R, Nolan B, Liesner R, et al. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost 2015; 13(6): 967-77.
10. Berntorp E, Negrier C, Gozzi P, Blaas PM, Lethagen S. Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc. Haemophilia 2016; 22(5): 389-96.
11. Mannucci PM, Mancuso ME, Franchini M. Tailoring hemostatic therapies to lower inhibitor development in previously untreated patients with severe hemophilia A. J Thromb Haemost 2016; 14(7): 1330-36.
12. Ljung RCR. Prevention and management of bleeding episodes in children with hemophilia. Paediatr Drugs 2018; 20(5): 455-64.

13. Shapiro AD, Ragni MV, Kulkarni R, Oldenberg J. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. J Thromb Haemost 2014; 12(11): 1788-800.

14. Manco-Johnson MJ, Kempton CL, Reding MT, Lissitchkov T, Goranov S, Gercheva L, et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost 2013; 11(6): 1119-27.

15. Sidharthan N, Sudevan R, Narayana PV, Mathew S, Raj M, Viswam D. Low dose secondary/tertiary prophylaxis is feasible and effective in resource limited setting in south India for children with Hemophilia. AM SOC Haematol 2017; 1(1): 1-3.

16. Driessler F, Miguelino MG, Pierce GF, Peters RT, Sommer JM. Evaluation of recombinant factor VIII Fc (Eloctate) activity by thromboelastometry in a multicenter phase 3 clinical trial and correlation with bleeding phenotype. Blood Coagul Fibrinolysis 2017; 28(7): 540-50.

17. Ragni MV, Malec LM. Design of the INHIBIT trial: preventing inhibitors by avoiding ‘danger’, prolonging half-life and promoting tolerance. Expert Rev Hematol 2014; 7(6): 747-55.

18. Raso S, Hermans C. Recombinant factor VIII: past, present and future of treatment of hemophilia A. Drugs Today (Barc) 2018; 54(4): 269-81.

19. Kis-Toth K, Rajani GM, Simpson A, Henry KL, Dumont J, Peters RT, et al. Recombinant factor VIII Fc fusion protein drives regulatory macrophage polarization. Blood Adv 2018; 2(21): 2904-16.